Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 27, 2023
Product Development
Nov. 27 Quick Takes: BioNTech grows U.K. presence
Plus: FDA approval for SpringWorks, setback for Aldeyra and updates from Sanofi, Regeneron, GSK, Abeona, Roivant, Sosei Heptares, Xenon, Arvinas, Teva
BioCentury | Aug 31, 2023
Finance
Formulas for success from biotechs that leaped in value despite the downturn
Back to School 2023 identifies four themes among 17 companies that jumped a tier or increased their market cap over 200%
BioCentury | May 9, 2023
Deals
May 8 Quick Takes: EQRx reset brings end of China deals, layoffs
Plus: Legend’s $350M raise helps May follow-ons top April tally; ADC deals by Eisai-BlissBio, FibroGen-Fortis; and more
BioCentury | Mar 10, 2023
Regulation
March 9 Quick Takes: FDA panel backs Genentech’s Polivy
Plus: QurAlis, Ring raise venture rounds and updates from AZ, BMS and more
BioCentury | Feb 11, 2023
Product Development
Feb. 10 Quick Takes: Aristea dissolving after safety findings
Plus: Abecma more than triples PFS in triple-class MM, and updates from Genentech, Phathom, Blueprint and more
BioCentury | May 13, 2020
Emerging Company Profile
QurAlis taking three ALS programs toward clinic with $42M series A
A broadened investor syndicate will help QurAlis advance programs targeting disease subpopulations
BioCentury | Dec 3, 2019
Company News
Xenon licenses sodium channel inhibitors to Neurocrine to fund more advanced epilepsy programs
Items per page:
1 - 10 of 14